CSL (ASX:CSL) share price lifts amid ASX 200's best day in 8 weeks

It has been a good day for the global biotech's shareholders…

| More on:
Lab worker puts hands in the air and dances around

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Ltd (ASX: CSL) share price edged higher today despite no news having been released by the global biotech.

However, the S&P/ASX 200 Index (ASX: XJO) has had its best day over the past 2 months, buoyed by positive investor sentiment.

At the closing bell, the CSL share price finished up 1.13% to $308.32. In comparison, the ASX 200 Index ended the day 0.58% higher at 7,460 points.

A recap on CSL's performance

Last month, CSL provided investors with its full-year scorecard for the 2021 financial period.

The group delivered a strong result against a backdrop of very challenging conditions brought on by the global COVID-19 pandemic.

Regardless of the uncertainty and complexities faced, CSL's Behring and Seqirus businesses recorded robust growth. However, the CSL share price fell on the result.

CSL Behring revenue rose by 6% thanks to strong demand for its immunoglobulin portfolio. This was led by its market-leading subcutaneous product, Hizentra. Sales rose 15%, driven by a preference for home administration and uptake for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

On the other hand, its influenza vaccines business, Seqirus, recorded an exceptionally strong performance with revenue up by 30% (constant currency). This was driven by record demand for seasonal influenza vaccines.

CSL noted that COVID-19 presented challenges for the collection of plasma, an essential raw material used in the production of its therapies.

Current plasma numbers are said to be around 20% below the levels recorded in FY20.

While plasma collections across the industry were adversely impacted, the company implemented multiple initiatives to mitigate this. As such, 25 new facilities were opened to attract lapsed and new donors through its doors.

Furthermore, marketing initiatives were also implemented to draw back its existing customer base.

In FY22, the company plans to open another 40 centres, expanding its presence mostly across the United States.

More on the CSL share price

Uncharacteristically, it has been a turbulent year for CSL shareholders. The CSL share price has recorded a modest gain of around 6% over the past 12 months. Year-to-date, the company's shares are up by around 8%.

CSL has a price-to-earnings (P/E) ratio of 38.55 and commands a market capitalisation of roughly $140.4 billion.

Motley Fool contributor Aaron Teboneras owns shares of CSL Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Healthcare Shares

Cochlear shares sink 9% on guidance downgrade

Investors haven't responded positively to this update. Let's dig deeper into it.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Telix shares push higher on investor day update

This radiopharmaceuticals company has grand plans for the future.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

3 leading ASX healthcare shares with global reach

These 3 healthcare companies are having an outsized impact far beyond local markets.

Read more »

Man looks shocked as he works on laptop on top a skyscraper with stockmarket figures in graphic behind him.
Healthcare Shares

Macquarie tips more than 100% upside for this ASX All Ords healthcare stock

This company could be set to soar.

Read more »

A little boy, soon to be a brother, kisses and holds his mum's pregnant tummy.
Healthcare Shares

Monash IVF shares fall 25% following second embryo incident

Its been a forgettable start to 2025 for Monash IVF shareholders.

Read more »

Shot of two young scientists using a laptop in a laboratory.
Healthcare Shares

Buying CSL shares? Meet your new board director

CSL’s new board director has spent the last 11 years in an executive role at Australia’s $240 billion Future Fund.

Read more »

A man sits in contemplation on his sofa looking at his phone as though he has just heard some serious or interesting news.
Technology Shares

Up 60% in two months, is it too late to buy Pro Medicus shares?

Pro Medicus has been delivering solid returns for years. Can the trend continue?

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why this ASX All Ords stock is jumping 9% today

What has put a rocket under this stock on Friday? Let's find out.

Read more »